Table 21 (abstract P54). See text for description
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
ALL MCP (2-5) -DEMRIQ inflammation | Global clinical scores-AJ | Outcome | ||||||
|---|---|---|---|---|---|---|---|---|
Patient | Baseline | 3 mo | 6 mo | Pearson’s correlation | Baseline | 3 mo | 6 mo | |
1 | 117,83 | 151,14 | 135,66 | Moderate (+) | 13 | 5 | 7 | Switch DMARD |
2 | 83,16 | 28,96 | 64,89 | Very strong (-) | 8 | 3 | 0 | Continue DMARD |
3 | 99,28 | 46,16 | 26,35 | Very strong (-) | 9 | 2 | 11 | Improved later |
4 | 38,28 | 104,71 | 87,86 | Strong (+) | 12 | 6 | 0 | Flare at 6 mo |
5 | 113,36 | 102,6 | 118,39 | Moderate (+) | 12 | 4 | 0 | Flare at 6 mo |
6 | 29,28 | 39,09 | 58,12 | Weak | 8 | 6 | 0 | Flare at 2 mo |
7 | 38,1 | 19,59 | 56,47 | Strong (+) | 13 | 0 | 0 | Flare at 3 mo |
8 | 50,42 | 96,76 | 74,75 | Moderate (-) | 7 | 2 | 0 | Flare at 3 mo |